Active Ingredient(s): Conivaptan Hydrochloride
FDA Approved: * December 29, 2005
Pharm Company: * ASTELLAS
Category: Diuretic

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Vaprisol Overview

Conivaptan, sold under the brand name Vaprisol, is a non-peptide inhibitor of the receptor for anti-diuretic hormone, also called vasopressin. It was approved in 2004 for hyponatremia (low blood sodium levels). The compound was discovered by Astellas and marked in 2006. The drug is now marketed by Cumberland Pharmaceuticals, Inc. Conivaptan inhibits two of the three subtypes of the vasopressin receptor (V1a and V2). Effectively, it causes iatrogenic nephrogenic diabetes insipidus. Conivaptan...

Read more Vaprisol Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Vaprisol Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Conivaptan Hydrochloride
  • Injection: 20mg, 20mg/100ml (0.2mg/ml), 20mg/100ml(0.2mg/ml), 20mg/4ml (5mg/ml)
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Vaprisol: (1 result)

Sorted by National Drug Code
  • 0469-1602 Vaprisol 20 mg/100ml Intravenous Solution by Astellas Pharma Us, Inc.

Other drugs which contain Conivaptan Hydrochloride or a similar ingredient: (2 results)